Transfusion-transmitted diseases: Risks, prevention and perspectives

European Journal of Haematology

Volumn 62, Issue 1, 1999, Pages 1-18

  Moor, Anne C E ^a,c   Dubbelman, Tom M A R ^a   VanSteveninck, John ^a   Brand, Anneke ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Bloodbank   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Prion; Review; Risk; Transfusion; Transmission; Virus

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BACTERIUM CONTAMINATION; BLOOD TRANSFUSION; CREUTZFELDT JAKOB DISEASE; DELTA AGENT HEPATITIS; DISEASE TRANSMISSION; HEPATITIS A; HEPATITIS B; HEPATITIS C; HEPATITIS E; HEPATITIS G VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 1; INFECTION RISK; PARASITE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCREENING; SYPHILIS; VIRUS TRANSMISSION;

EID: 0032914918     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1999.tb01108.x     Document Type: Review

References (183)

1. NISHIZAWA T, OKAMOTO H, KONISHI K, YOSHIZAWA H, MIYAKAWA Y, MAYUMI M. A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology. Biochem Biophys Res Commun 1997;241:92-97.
2. BLAJCHMAN MA, KLEIN HG. Looking back in anger: retrospection in the face of a paradigm shift. Transfusion Med Rev 1997;XI:1-5.
3. GALLO RC, SARIN PS, GELMAN EP, et al. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 1983;220:865-867.
4. BARRE-SINOUSSI F, CHERMANN JC, REY F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868-871.
5. O'BRIEN SJ, GOEDERT JJ. HIV causes AIDS: Koch's postulates fullfilled. Curr Opin Immunol 1996;8:613-618.
6. UNAIDS/WHO working group on global HIV/AIDS and STD surveillance. Report on the global HIV/AIDS epidemic, Geneva, Switzerland, 1997.
7. CHARNEAU P, BORMAN AM, QUILLENT C, et al. Isolation and envelope sequence of a highly divergent HIV-1 isolate: definition of a new HIV-1 group. Virology 1994;205:247-253.
8. BARIN F, BOUP MS, DENIS F, et al. Serological evidence for virus related to simian T-lymphotropic retrovirus III in residents of West Africa. Lancet 1985;ii:1387-1389.
9. MARLINK R. Lessons from the second AIDS virus, HIV-2. AIDS 1996;10:689-699.
10. Center for Disease Control. Possible transfusion-associated acquired immunodeficiency syndrome (AIDS)-California. Morb Mortal Wkly Rep 1982;31:652-654.
11. Center for Disease Control. Prevention of acquired immune deficiency syndrome (AIDS): report of inter-agency recommendations. Morb Mortal Wkly Rep 1983;32:101-103.
12. MUNOZ A, SABIN CA, PHILIPS AN. The incubation period of AIDS. AIDS 1997;11:S69-S76.
13. Center for Disease Control and Prevention. HIV/AIDS surveillance report 1997;9:8.
14. EUROPEAN CENTRE FOR EPIDEMIOLOGICAL MONITORING OF AIDS. HIV/AIDS Surveillance in Europe: quarterly report 1997: No. 54.
15. KLEINMAN S, BUSCH MP, KORELITZ JJ, SCHREIBER GB. The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection. Transfusion Med Rev 1997;XI:155-172.
16. FRANCESCHI S, DALMASO L, LAVECCHIA C. Trends in incidence of AIDS associated with transfusion of blood and blood products in Europe and the United States, 1985-93. Br Med J 1995;311:1534-1536.
17. DALMASO L, FRANCESCHI S, LORE A, DEANGELIS V, LAVECCHIA C. Lack of correlation between the incidence of bloodborne AIDS and overall AIDS incidence in Western Europe. Transfusion 1997;37:221-225.
18. SELIK RM, WARD JW, BUEHLER JW. Demographic differences in cumulative incidence rates of transfusion-associated acquired immunodeficiency syndrome. Am J Epidemiol 1994;140:105-112.
19. LEPONT F, COSTAGLIOLA D, MASSARI V, VALLERON AJ. Estimation of the size of the HIV/AIDS epidemic due toblood transfusion in France. Int J Epidemiol 1995;24:441-445.
20. LAVECCHI C, DALMASO L, FRANCESCHI S, SERRAINO D. AIDS in transfusion recipients and hemophiliacs in France and other European countries. J Acq Imm Def Syndr Hum Retrovirol 1996;11:512-514.
21. POIESZ BJ, RUSCETTI FW, GAZDAR AF, BUNN PA, MINNA JD, GALLO RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980;77:7415-7419.
22. KALYANARAMAN VS, SARNGADHARAN MG, ROBERT-GUROFF M, MIYOSHI I, GOLDE D, GALLO RC. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science 1982;218:571-573.
23. VRIELINK H, ZAAIJER HL, REESINK HW. The clinical relevance of HTLV type I and II in transfusion medicine. Transfusion Med Rev 1997;XI:173-179.
24. SANDLER SG, FANG CT, WILLIAMS AE. Human T-cell lymphotropic virus type I and II in transfusion medicine. Transfusion Med Rev 1991;V:93-107.
25. OKOCHI K, SATO H, HINUMA Y. A retrospective study on transmission of adult T cell leukemia virus by blood transfusion: seroconversion in recipients. Vox Sang 1984;46:245-253.
26. SCHREIBER GB, MURPHY EL, HORTON JA, et al. Risk factors for human T-cell lymphotropic virus types I and II (HTLV-I and -II) in blood donors: the retrovirus epidemiology donor study. J Acq Imm Def Syndr Hum Retrovirol 1997;14:263-271.
27. DONEGAN E, LEE H, OPERSKALSKI EA, et al. Transfusion transmission of retroviruses: human T-lymphotropic virus types I and II compared with human immunodeficiency virus type I. Transfusion 1994;34:478-483.
28. PAGLIUCA A, PAWSON R, MUETI GJ. HTLV-I screening in Britain - time for a reappraisal. Br Med J 1995;311:1313- 1314.
29. TOBLER LH, BUSCH MP. History of posttransfusion hepatitis. Clin Chem 1997;43:1487-1493.
30. MAMIYA N, WORMAN HJ. Epidemiology, prevention, clinical features and therapy of hepatitis B, C, and G. Curr Opin Inf Dis 1997;10:390-397.
31. KORFLITZ JJ, BUSCH MP, KLEINMAN SH, et al. A method for estimating hepatitis B virus incidence rates in volunteer blood donors. National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study. Transfusion 1997;37:634-640.
32. SEEFF LB. Transfusion-associated hepatitis B: past and present. Transfusion Med Rev 1988;II:204-214.
33. HOOFNAGLE JH. Posttransfusion hepatitis B. Transfusion 1990;30:384-386.
34. BARBARA JA. Hepatitis B: old virus, new problems? Vox Sang 1994;67:239-242.
35. ELGHOUZZI MH, COUROUCE AM, MAGNIUS LO, LUNEL F, LAPIERRE V. Transmission of hepatitis B virus by HBV-negative blood transfusion. Lancet 1995;346:964.
36. JONGERIUS JM, VAN DER POEL CL, VAN LEEUWEN EF. A simple strategy to look back on posttransfusion hepatitis B in a multitransfused patient. Vox Sang 1988:75:66-69.
37. RIZZETTO M, PONZETTO A, MARINUCCI G. Transfusion-related delta hepatitis. Transfusion Med Rev 1988;II:224-228.
38. AACH RD, STEVENS CE, HOLLINGER FB, et al. Hepatitis C virus infection in post-transfusion hepatitis. An analysis with first- and second-generation assays. N Engl J Med 1991;325:1325-1329.
39. CHOO QL, KUO G, WEINER AJ, OVERBY LR, BRADLEY DW, HOUGHTON M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-362.
40. GILL P. Transfusion-associated hepatitis C: reducing the risk. Transfusion Med Rev 1993;VII:104-111.
41. ALTER HJ. To C or not to C: these are the questions. Blood 1995;85:1681-1695.
42. CONRY-CANTILENA C, VANRADEN M, GIBBLE J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996;334:1691-1696.
43. ZEUZEM S, TEUBER G, LEE JH, RUSTER B, ROTH WK. Risk factors for the transmission of hepatitis C. J Hepatol 1996;24:3-10.
44. TOBLER LH, BUSCH MP, PETERSON J, KOCHESKY R, BAHL C, LEE SR. Identification of a crossreactive epitope within hepatitis C virus core antigen: resolution by third-generation hepatitis C virus assays. Transfusion 1996;36:581-582.
45. BLANCHETTE V, WALKER I, GILL P, ADAMS M, ROBERTS R, INWOOD M. Hepatitis C infection in patients with hemophilia: results of a national survey. Canadian Hemophilia Clinic Directors Group. Transfusion Med Rev 1994;VIII:210-217.
46. Center for Disease Control. Outbreak of hepatitis C associated with intravenous immunoglobulin administration-United States, October 1993-June 1994. Morb Mortal Wkly Rep 1994;43:505-509.
47. LEFERE JJ, LOISEAU P, MARTINOT-PEIGNOUX M, et al. Infection by hepatitis C virus through contaminated intravenous immune globulin: results of a prospective national inquiry in France. Transfusion 1996;36:394-397.
48. YAP PL. The viral safety of intravenous immune globulin. Clin Exp Immunol 1996;104:35-42.
49. DODD RY. Infectious risk of plasma donations: relationship to safety of intravenous immune globulins. Clin Exp Immunol 1996;104:31-34.
50. MANNUCCI PM, GDOVIN S, GRINGERI A, et al. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. Ann Int Med 1994;120:1-7.
51. LEMON SM. The natural history of hepatitis A: the potential for transmission by transfusion of blood or blood products. Vox Sang 1994;67:19-23.
52. VERMIJLEN J, PEERLINCK K. Review of the hepatitis A epidemics in hemophiliacs in Europe. Vox Sang 1994;67:8-11.
53. MANNUCCI PM, SANTAGOSTINO E, DI BONA E, et al. The outbreak of hepatitis A in Italian patients with hemophilia: facts and fancies. Vox Sang 1994;67:31-35.
54. PURCELL RH, MANNUCCI PM, GDOVIN S, et al. Virology of the hepatitis A epidemic in Italy. Vox Sang 1994;67:2-7.
55. Center for Disease Control. Hepatitis A among persons with hemophilia who received clotting factor concentrate - United States, September-December 1995. Morb Mortal Wkly Rep 1996;45:29-32.
56. SHAPIRO CN. Transmission of hepatitis viruses. Ann Int Med 1994;120:82-84.
57. Center for Disease Control. Hepatitis E among U.S. travelers, 1989-1992. Morb Mortal Wkly Rep 1993;42:1-4.
58. ZAAIJER HL, KOK M, LELIE PN, TIMMERMAN RJ, CHAU K, VANDER PAL HJ. Hepatitis E in The Netherlands: imported and endemic. Lancet 1993;341:826.
59. ZAAIJER HL, MAUSERBUNSCHOTEN EP, TENVEEN JH, et al. Hepatitis E virus antibodies among patients with hemophilia, blood donors, and hepatitis patients. J Med Virol 1995;46:244-246.
60. WANG CH, FLEHMIG B, MOECKLI R. Transmission of hepatitis E virus by transfusion?. Lancet 1993;341:825-826.
61. SYLVAN SP, HELLSTROM UB, HAMPI H, KAPPRELL HP, TROONEN H. Hepatitis E in patients with chronic autoimmune liver disease. JAMA 1995;273:377-378.
62. MANNUCCI PM, GRINGERI A, SANTAGOSTINO E, ROMANO L, ZANETTI A. Low risk of transmission of hepatitis E virus by large-pool coagulation factor concentrates. Lancet 1994;343:597-598.
63. MATEOS ML, LASA E, CAMARERO C, BAQUERO F, HELLIN J. Is hepatitis E virus transfusion transmitted to children? Transfusion Med 1997;7:319-320.
64. LINNEN J, WAGES J, JR. ZHANG-KECK ZY, et al. Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 1996;271:505-508.
65. SIMONS JN, LEARY TP, DAWSON GJ, et al. Isolation of novel virus-like sequences associated with human hepatitis. Nature Med 1995;1:564-569.
66. KARAYIANNIS P, THOMAS HC. Current status of hepatitis G virus (GBV-C) in transfusion: is it relevant? Vox Sang 1997;73:63-69.
67. ALTER HJ, NAKATSUJI Y, MELPOLDER J, et al. The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease. N Engl J Med 1997;336:747-754.
68. SHIMIZU MH, OSADA K, OKAMOTO H. Transfusion-transmitted hepatitis G virus following open heart surgery. Transfusion 1996;36:937.
69. SHIMIZU M, OSADA K, OKAMOTO H. Transmission of GB virus C by blood transfusions during heart surgery. Vox Sang 1997;72:76-78.
70. WANG JT, TSAI FC, LEE CZ, et al. A prospective study of transfusion-transmitted GB virus C infection: similar frequency but different clinical presentation compared with hepatitis C virus. Blood 1996;88:1881-1886.
71. JARVIS LM, DAVIDSON F, HANLEY JP, YAP PL, LUDLAM CA, SIMMONDS P. Infection with hepatitis G virus among recipients of plasma products. Lancet 1996;348:1352-1355.
72. ALTER HJ. G-pers creepers, where'd you get those papers? A reassessment of the literature on the hepatitis G virus. Transfusion 1997;37:569-572.
73. MIYAKAWA Y, MAYUMI M. Hepatitis G virus - a true hepatitis virus or an accidental tourist? N Engl J Med 1997;336:795-796.
74. ALTER HJ. The cloning and clinical implications of HGV and HGBV-C. N Engl J Med 1996;334:1536-1537.
75. BARBARA JAJ. Does GB virus C ("hepatitis G virus") threaten the safety of our blood supply? Transfusion Med 1997;7:75-76.
76. ALTER MJ, GALLAGHER M, MORRIS TT, et al. Acute non-A-E hepatitis in the United States and the role of hepatitis G virus infection. Sentinel Counties Viral Hepatitis Study Team. N Engl J Med 1997;336:741-746.
77. BYRNES JJ, BANKS AT, PIATACK M, JR, KIM JP. Hepatitis G-associated aplastic anaemia. Lancet 1996;348:472.
78. ZAIDI Y, CHAPMAN CS, MYINT S. Aplaslic anaemia after HGV infection. Lancet 1996;348:471-472.
79. BROWN KE, WONG S, YOUNG NS. Prevalence of GBV-C/ HGV, a novel "hepatitis" virus, in patients with aplastic anaemia. Br J Haematol 1997;97:492-496.
80. BROWN KE, YOUNG NS. Parvovirus B19 in human disease. Annu Rev Med 1997;48:59-67.
81. PARDI DS, ROMERO Y, MERTZ LE, DOUGLAS DD. Hepatitis-associated aplastic anemia and acute parvovirus B19 infection: a report of two cases and a review of the literature. Am J Gastroenterol 1998;93:468-470.
82. PROWSE C, LUDLAM CA, YAP PL. Human parvovirus B19 and blood products. Vox Sang 1997;72:1-10.
83. COHEN BJ, BEARD S, KNOWLES WA, et al. Chronic anemia due to parvovirus B19 infection in a bone marrow transplant patient after platelet transfusion. Transfusion 1997;37:947-952.
84. LUBAN NLC. Human parvoviruses: implications for transfusion medicine. Transfusion 1994;34:821-827.
85. TEGTMEIER GE. Posttransfusion cytomegalovirus infections. Arch Pathol Lab Med 1989;113:236-245.
86. BOWDEN RA. Transfusion-transmitted cytomegalovirus infection. Immunol Invest 1995;24:117-128.
87. VAN DER POEL C, NOEL L, BARBARA J, DODD R. ISBT working party on transmissible diseases: report on the workshop "infectious-disease testing and quality control". Vox Sang 1996;70:53-60.
88. DE GRAAN-HENTZEN YCE, GRATAMA JW, MUDDE GC, et al. Prevention of primary cytomegalovirus infection in patients with hematologic malignancies by intensive white cell depletion of blood products. Transfusion 1989;29:757-760.
89. BOWDEN RA, SLICHTER SJ, SAYERS M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) scronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995;86:3598-3603.
90. BOWDEN RA, SLICHTER S, SAYERS M, WEISDORF D, FISHER L. Safety of filtered leukocyte-reduced blood products for prevention of transfusion-associated cytomegalovirus infection - response. Blood 1996;87:4910-4911.
91. LANDAW EM, KANTER M, PETZ LD. Safety of filtered leukocyte-reduced blood products for prevention of transfusion-associated cytomegalovirus infection. Blood 1996;87:4910.
92. JAMES DJ, SIKOTRA S, SIVAKUMARAN M, et al. The presence of free infectious cytomegalovirus (CMV) in the plasma of donated CMV-seropositive blood and platelets. Transfusion Med 1997;7:123-126.
93. LUPPI M, TORELLI G. The new lymphotropic herpesviruses (HHV-6, HHV-7, HHV-8) and hepalitis C virus (HCV) in human lymphoproliferative diseases: an overview. Haematologica 1996;81:265-281.
94. LUSSO P, GALLO RC. Human herpesvirus 6 in AIDS. Immunol Today 1995;16:67-71.
95. BRAUN DK, DOMINGUEZ G, PELLETT PE. Human herpesvirus 6. Clin Microbiol Rev 1997;10:521-567.
96. LUPPI M, BAROZZI P, MARASCA R, CECCHERININELLI L, CECCHERELLI G, TORELLI G. Human herpesvirus-6 (HHV-6) in blood donors. Br J Haematol 1995;89:943-945.
97. RICKINSON AB. Changing seroepidemiology of HHV-8. Lancet 1996;348:1110-1111.
98. BLACKBOURN DJ, AMBROZIAK J, LENNETTE E, ADAMS M, RAMACHANDRAN B, LEVY JA. Infeclious human herpesvirus 8 in a healthy North American blood donor. Lancet 1997;349:609-611.
99. OPERSKALSKI EA, BUSCH MP, MOSLEY JW, KEDES DH. Blood donations and viruses. Lancet 1997;349:1327.
100. LEFERE JJ, MARIOTTI M, GIROT R, LOISEAU P, HERVE P. Transfusional risk of HHV-8 infection. Lancet 1997;350:217.
101. ALLAIN JP. Screening blood donors for markers of new viruses. Lancet 1997;349:584-585.
102. CABLE RG. Evaluation of syphilis testing of blood donors. Transfusion Med Rev 1996;X:296-302.
103. HERRERA GA, LACKRITZ EM, JANSSEN RS, et al. Serologic test for syphilis as a surrogate marker for human immunodeficiency virus infection among United States blood donors. Transfusion 1997;37:836-840.
104. SEIDL S. Syphilis screening in the 1990's. Transfusion 1990;30:773-774.
105. WENDEL S. Current concepts on transmission of bacteria and parasites by blood components. Vox Sang 1994;67:161-174.
106. DE SCHRYVER A, MEHEUS A. Syphilis and blood transfusion: a global perspective. Transfusion 1990;30:844-847.
107. RICKETTS MN, CASHMAN NR, STRATTON EE, ELSAADANY S. Is Creutzfeldt-Jakob disease transmitted in blood? Emerg Infect Dis 1997;3:155-163.
108. HAYWOOD AM. Transmissible spongiform encephalopathies. N Engl J Med 1997;337:1821-1828.
109. MENACHE D, O'MALLEY JP. Creutzfeldt-Jakob disease: current U.S. policy to further reduce the possible risk of transmission by transfusion. Biologicals 1996;24:277-283.
110. WILL RG, IRONSIDE JW, ZEIDLER M, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996;347:921-925.
111. DEALLER S. A matter for debate: the risk of bovine spongiform encephalopathy to humans posed by blood transfusion in the UK. Transfusion Med 1996;6:217-222.
112. FLANAGAN P, BARBARA JAJ. Prion disease and blood transfusion. Transfusion Med 1996;6:213-215.
113. KLEIN MA, FRIGG R, FLECHSIG E, et al. A crucial role for B cells in neuroinvasive scrapie. Nature 1997;390:687-690.
114. LUDLAM CA. New-variant Creutzfeldt-Jakob disease and treatment of haemophilia. Lancet 1997;350:1704.
115. TAYLOR F. Transfusion-associated malaria. Emerg Infect Dis 1996;2:152.
116. ZUCKER JR. Changing patterns of autochthonous malaria transmission in the United Stales: a review of recent outbreaks. Emerg Infect Dis 1996;2:37-43.
117. REESINK HW, DODD RY, LEIKOLA J, et al. How far shall we go in the predonation selection of blood donors to safeguard patients for blood-transfusion-related infections? Vox Sang 1993;65:1-9.
118. SCHMUNIS GA. Trypanosoma cruzi, the etiologic agent of Chagas' disease: status in the blood supply in endemic and non-endemic countries. Transfusion 1991;31:547-557.
119. WENDEL S, GONZAGA AL. Chagas' disease and blood transfusion: a New World problem? Vox Sang 1993;64:1-12.
120. MORAES-SOUZA H, BORDIN JO. Strategies for the prevention of transfusion-associated Chagas' disease. Transfusion Med Rev 1996;X:161-170.
121. SHULMAN IA, APPLEMAN MD, SAXENA S, HITI AL, KIRCHHOFF LV. Specific antibodies to Trypanosoma cruzi among blood donors in Los Angeles, California. Transfusion 1997;37:727-731.
122. GALEL SA, KIRCHHOFF LV. Risk factors for Trypanosoma cruzi infection in California blood donors. Transfusion 1996;36:227-231.
123. MINTZ ED, ANDERSON JF, CABLE RG, HADLER JL. Transfusion-transmitted babesiosis: a case report from a new endemic area. Transfusion 1991;31:365-368.
124. BLANCO C. Emerging infections: what's the risk? Abstract, Third Annual CHI meeting on Blood Safety and Screening, McLean, VA, 1997.
125. HERWALDT BL, KJEMTRUP AM, CONRAD PA, et al. Transfusion-transmitted babesiosis in Washington State: first reported case caused by a WA1-type parasite. J Infect Dis 1997;175:1259-1262.
126. SHULMAN IA. Parasitic infections and their impact on blood donor selection and testing. Arch Pathol Lab Med 1994;118:366-370.
127. NELSON JC, KAUFFMANN DJ, CIAVARELLA D, SENISI WJ. Acquired toxoplasmic retinochoroiditis after platelet transfusions. Ann Ophtalmol 1989:21:253-254.
128. BLAJCHMAN MA, ALI AM, RICHARDSON HL. Bacterial contamination of cellular blood components. Vox Sang 1994;67:25-33.
129. SAZAMA K. Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion 1990;30:583-590.
130. HOGMAN CF. Adverse effects: bacterial contamination (including shelf life). A brief review of bacterial contamination of blood components. Vox Sang 1996;70:78-82.
131. GOLDMAN M, BLAJCHMAN MA. Blood product-associated bacterial sepsis. Transfusion Med Rev 1991;V:73-83.
132. AUBUCHON JP, KRUSKALL MS. Transfusion safety: realigning efforts with risks. Transfusion 1997;37:1211-1216.
133. KLEIN HG, DODD RY, NESS PM, FRATANTONI JA, NEMO GJ. Current status of microbial contamination of blood components: summary of a conference. Transfusion 1997;37:95-101.
134. DODD RY. Hepatitis C virus, antibodies, and infectivity. Paradox, pragmatism, and policy. Am J Clin Pathol 1992;97:4-6.
135. LOIACONO BR, CARTER GR, CARTER CS, LEITMAN SF, KLEIN HG. Efficacy of various methods of confidential unit exclusion in identifying potentially infectious blood donations. Transfusion 1989;29:823-826.
136. PETERSEN LR, LACKRITZ E, LEWIS WF, et al. The effectiveness of the confidential unit exclusion option. Transfusion 1994;34:865-869.
137. SCHREIBER GB, BUSCH MP, KLEINMAN SH, KORELITZ JJ. The risk of transfusion-transmitted viral infections. N Engl J Med 1996;334:1685-1690.
138. WILLIAMS AE, THOMSON RA, SCHREIBER GB, et al. Estimates of infectious disease risk factors in US blood donors. Retrovirus Epidemiology Donor Study. JAMA 1997;277:967-972.
139. REESINK HW, ENGELFRIET CP, DODD RY, et al. What are the consequences of indeterminate results in confirmatory tests for antibodies against transmissible viruses? Vox Sang 1997;73:97-104.
140. DODD RY, REESINK HW, BUSCH MP, et al. Do surrogate tests improve the safety of the blood supply? Vox Sang 1995;69:280-291.
141. BUSCH MP. To thy (reactive) donors be true. Transfusion 1997;37:117-120.
142. BUSCH MP, KORELITZ JJ, KLEINMAN SH, LEE SR, AUBUCHON JP, SCHREIBER GB. Declining value of alanine amino-transferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study. Transfusion 1995;35:903-910.
143. MOLIGN MH, VANDER LINDEN JM, KO LK, GORGELS J, HOP W, VAN RHENEN DJ. Risk factors and anti-HBc reactivity among first time blood donors. Vox Sang 1997;72:207-210.
144. BUSCH MP, DODD RY, LACKRITZ EM, AUBUCHON JP, BIRKMEYER JD, PETERSEN LR. Value and cost-effectiveness of screening blood donors for antibody to hepatitis B core antigen as a way of detecting window-phase human immunodeficiency virus type 1 infections. Transfusion 1997;37:1003-1011.
145. ABULRAHI HA, BOHLEGA EA, FONTAINE RE, AL-SEGHAYER SM, AL-RUWAIS AA. Plasmodium falciparum malaria transmitted in hospital through heparin locks. Lancet 1997;349:23-25.
146. ESTEBAN JI, GOMEZ J, MARTELL M, et al. Transmission of hepatitis C virus by a cardiac surgeon. N Engl J Med 1996;334:555-560.
147. TEDDER RS, ZUCKERMAN MA, GOLDSTONE AH, et al. Hepatitis B transmission from contaminated cryopreservation tank. Lancet 1995;346:137-140.
148. ALLANDER T, GRUBER A, NAGHAVI M, et al. Frequent patient-to-patient transmission of hepatitis C virus in a haematology ward. Lancet 1995;345:603-607.
149. AUBUCHON JP, BIRKMEYER JD, BUSCH MP. Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood. Transfusion 1997;37:45-51.
150. LACKRITZ EM, SATTEN GA, ABERLEGRASSE J, et al. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med 1995;333:1721-1725.
151. COUROUCE AM, PILLONEL J. Transfusion-transmitted viral infections. Relrovirus and Viral Hepatitis Working Groups of the French Society of Blood Transfusion. N Engl J Med 1996;335:1609-1610.
152. RIGGER J, SCHWARTZ DW, UY A, et al. Risk of hepatitis C virus (HCV) transmission by anti-HCV-negative blood components in Austria and Germany. Ann Hematol 1996;72:35-39.
153. SCHWARTZ DWM, SIMSON G, BAUMGARTEN K, et al. Risk of human immunodeficiency virus (HIV) transmission by anti-HIV-negative blood components in Germany and Austria. Ann Hematol 1995;70:209-213.
154. WHYTE GS, SAVOIA HF. The risk of transmitting HCV, HBV or HIV by blood transfusion in Victoria. Med J Aust 1997;166:584-586.
155. REMIS RS, DELAGE G, PALMER RW. Risk of HIV infection from blood transfusion in Montreal. Can Med Assoc J 1997;157:375-382.
156. Center for Disease Control. Persistent lack of detectable HIV-1 antibody in a person with HIV infection-Utah, 1995. Morb Mortal Wkly Rep 1996;45:181-185.
157. SORIANO V, DRONDA F, GONZALEZ-LOPEZ A, et al. HIV-1 causing AIDS and death in a seronegative individual. Vox Sang 1994;67:410-411.
158. MARTIN-RICO P, PEDERSEN C, SKINHOJ P, NIELSEN C, LINDHARDT BO. Rapid development of AIDS in an HIV-1-antibody-negative homosexual man. Aids 1995;9:95-96.
159. ALTER MJ, MARGOLIS HS, KRAWCZYNSKI K, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992;327:1899-1905.
160. HU DJ, DONDERO TJ, RAYFIELD MA, et al. The emerging genetic diversity of HIV. The importance of global surveillance for diagnostics, research, and prevention. JAMA 1996;275:210-216.
161. BARIN F, COUROUCE AM, PILLONEL J, et al. Increasing diversity of HIV-1(M) serotypes in French blood donors over a 10-year period (1985-1995). Aids 1997;11:1503-1508.
162. PAU CP, HU DJ, SPRUILL C, et al. Surveillance for human immunodeficiency virus type 1 group O infections in the United States. Transfusion 1996;36:398-400.
163. LOUSSERT-AJAKA I, LY TD, CHAIX ML, et al. HIV-1/HIV-2 seronegativily in HIV-1 subtype O infected patients. Lancet 1994;343:1393-1394.
164. BUSCH MP, WATANABE K, SMITH JW, HERMANSEN S, THOMSON R. False negative (FN) testing errors in routine viral screening. Transfusion 1996;36:59S.
165. LINDEN JV. Error contributes to the risk of transmissible disease. Transfusion 1994;34:1016.
166. COURTOIS F, JULLIEN AM, CHENAIS F, NOEL L, PINON F. Transmission of HIV by transfusion of HIV-screened blood: the value of a national register. The "Recipients" Study Group of the French Society of Blood Transfusion. Transfusion Med 1992;2:51-55.
167. GIBBS WN, CORCORAN P. Blood safety in developing countries. Vox Sang 1994;67:377-381.
168. McFARLAND W, MVERE D, SHANDERA W, REINGOLD A. Epidemiology and prevention of transfusion-associated human immunodeficiency virus transmission in sub-Saharan Africa. Vox Sang 1997;72:85-92.
169. CONSTEN ECJ, VAN DER MEER JTM, DE WOLF F, HEU HA, HENNY PC, VAN LANSCHOT JJB. Risk of iatrogenic human immunodeficiency virus infection through transfusion of blood tested by inappropiately stored or expired rapid antibody assays in a Zambian hospital. Transfusion 1997;37:930-934.
170. CHUANSUMRIT A, VARAVITHYA W, ISARANGKURA P, et al. Transfusion-transmitted AIDS with blood negative for anti-HIV and HIV-antigen. Vox Sang 1996;71:64-65.
171. KITAYAPORN D, KAEWKUNGWAL J, BEJRACHANDRA S, RUNGROUNG E, CHANDANAYINYONG D, MASTRO TD. Estimated rate of HIV-1-infectious but seronegative blood donations in Bangkok, Thailand. AIDS 1996;10:1157-1162.
172. JAGER H, NGALY B, PERRIENS J, et al. Prevention of transfusion-associated HIV transmission in Kinshasa, Zaire: HIV screening is not enough. Aids 1990;4:571-574.
173. LACKRITZ EM, RUEBUSH TKD, ZUCKER JR, ADUNGOSI JE, WERE JB, CAMPBELL CC. Blood transfusion practices and blood-banking services in a Kenyan hospital. Aids 1993;7:995-999.
174. FOSTER S, BUVE A. Benefits of HIV screening of blood transfusions in Zambia. Lancet 1995;346:225-227.
175. PANOGRAHI AK, PANDA SK, DIXIT RK, et al. Magnitude of hepatitis C virus infection in India: prevalence in healthy blood donors, acute and chronic liver diseases. J Med Virol 1997;51:167-174.
176. COLEBUNDERS R, BEELAERT G, WELLENS R. HIV testing in developing countries. Lancet 1997;349:1258.
177. LACKRITZ EM, HIGHTOWER AW, ZUCKER JR, et al. Longitudinal evaluation of severely anemic children in Kenya: the effect of transfusion on mortality and hematologic recovery. AIDS 1997;11:1487-1494.
178. McFARLAND W, MVERE D, KATZENSTEIN D. Risk factors for prevalent and incident HIV infection in a cohort of volunteer blood donors in Harare, Zimbabwe: implications for blood safety. AIDS 1997;11:S97-S102.
179. NANU A, SHARMA SR, CHATTERJEE K, JYOTI P. Markers for transfusion-transmissible infections in North Indian voluntary and replacement blood donors: prevalence and trends 1989-1996. Vox Sang 1997;73:70-73.
180. WIDMANN FK. Transfusion medicine: accept no substitute. Lancet 1997;350:Sii27.
181. ROGERS PM, SALDANHA J, ALLAIN JP. Report of EPFA/ NIBSC workshop "Nucleic acid amplification tests (NAT) for the detection of blood-borne viruses" held on 31 October 1996 in Amsterdam, The Netherlands. Vox Sang 1997;72:199-206.
182. LIN L, COOK DN, WIESEHAHN GP, et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997;37:423-435.
183. BEN-HUR E, MOOR ACE, MARGOLIS-NUNNO H, et al. The photodecontamination of cellular blood components: mechanisms and use of photosensitization in transfusion medicine. Transfusion Med Rev 1996;X:15-22.